Your Road Map to the Future Begins Here
Alzheimer's Outlook 2014
Six leading experts provide the latest thinking on new and emerging approaches to the prevention, diagnosis and treatment of Alzheimer's disease and other dementias
If you or a loved one has been diagnosed with Alzheimer's disease or another memory disorder...
Or if you are caring for someone with Alzheimer's and are wondering if there's a new drug or therapy in the pipeline that might help...
Then it's vitally important to stay on top of developments in the field -- so you can ask your doctor the key questions -- and discuss the critical issues that affect the management of the disease.
To help you, we have just published Alzheimer's Outlook 2014 -- a valuable new resource that allows you to sit down with a group of preeminent physicians and listen in as they share their insights and ideas about the future course of Alzheimer's disease -- and provide a clear sense of what caregivers and patients can hope for.
Alzheimer's Outlook 2014 is part of a series of annual research reports written for concerned lay readers. It gives you special access to information you won't find anywhere else on the future of Alzheimer's research.
What's in the Alzheimer's pipeline?
In the past few years, researchers have made meaningful strides in the understanding of dementia prevention, diagnosis and treatment. Many important breakthroughs have come from the talented physicians and scientists working here at Johns Hopkins Medicine.
In the pages of Alzheimer's Outlook 2014 you'll gain unprecedented access to the insights of Hopkins experts, as well as from colleagues at other renowned research centers.
And there's so much exciting information to report!
Although we don't yet have a drug to stop the disease progression, new techniques in molecular biology and genetics are providing remarkable insights into how and why Alzheimer's begins, how it progresses and how it produces symptoms.
Great progress has also been made in brain imaging and other biomarkers that might allow us to diagnose Alzheimer's when no or minimal symptoms are present. Thanks to two new radiologic compounds researchers can now see the abnormal proteins in the brain and track the disease from one part of the brain to the next.
Here's a sample of other key highlights in Alzheimer's Outlook 2014:
- Investigating Causes and Risks by Peter V. Rabins, M.D., M.P.H., Professor of Psychiatry at Johns Hopkins and Medical Editor of the Johns Hopkins Memory Disorders Bulletin. Dr. Rabins takes a close look at the amyloid cascade hypothesis, which predominates Alzheimer's research and drug development. He also discusses promising new brain tracers, apolipoprotein E as a risk factor for late-onset Alzheimer's and progress on understanding the genetics of Alzheimer's.
- New Research Efforts to Prevent or Slow Dementia by Peter V. Rabins, M.D., M.P.H. Do vitamin E supplements have any effect on cognitive impairment or Alzheimer's disease? In his second chapter, Dr. Rabins reviews recent research on this question. He also reports on the role of statins in Alzheimer's, research on cocoa and enhanced brain health and the status of funding for dementia research.
- The Ongoing Search for Drugs That Will Affect Alzheimer's Disease by Paul Rosenberg, M.D., Associate Director of the Memory and Alzheimer's Treatment Center at the Johns Hopkins Bayview Medical Center. Researchers now believe that to have any significant benefit, a treatment has to stop the disease long before symptoms of Alzheimer's appear and before damage to the brain becomes widespread. Dr. Rosenberg describes efforts at early diagnosis, including the A4 trial, the DIAN study, the API study and the SNIFF study.
- Noninvasive Brain Stimulation for Aphasia by Argyle Hillis, M.D., Professor of Neurology at the Johns Hopkins University School of Medicine. Primary progressive aphasia causes degeneration of nerve cells in the brain's left hemisphere, which controls speech and language. It can also be an early symptom of Alzheimer's. Dr. Hillis describes her work with transcranial direct current stimulation to help aphasia patients recover.
- Reducing Risks for Alzheimer's by Marilyn Albert, Ph.D., Director of the Johns Hopkins Alzheimer's Disease Research Center. Aerobic exercise promotes better mental functioning by improving cerebral blood flow. But can exercise improve the outlook for Alzheimer's patients? Dr. Alpert looks at research on exercise and dementia and also reports good news on increased federal funding for dementia research.
- Assessing Cognitive Impairment Online by Jason Brandt, Ph.D., Professor of Neurology at the Johns Hopkins University School of Medicine. Low-tech cognitive screening tests offer a quick, inexpensive assessment of a person's cognitive health. Dr. Brandt has been working on an online assessment tool called the "Dementia Risk Assessment," which will help patients decide if they should pursue in-person evaluation from a doctor.
- Brain Training: The ACTIVE Study by George W. Rebok, Ph.D., Professor of Mental Health at the Johns Hopkins Bloomberg School of Public Health. Dr. Rebok is a principal investigator in the ACTIVE (Advanced Cognitive Training for Independent and Vital Elderly) trial which looks at ways to improve cognitive performance in older adults. In this section, Dr. Rebok explains what he discovered.
As we mentioned, Alzheimer's Outlook 2014 is part of a series of annual research updates on Alzheimer's and related dementias. As a buyer of this year's edition, you'll be among the first to be notified when the 2015 edition is published next year.
This is information so critical to being an informed patient that we want you to have it right away. We've created Alzheimer's Outlook 2014 as an instant PDF download to ensure that you can start reading this material today. You can be sure your copy will contain up-to-the minute information to help stay on top of the latest developments.
Still not sure you'll benefit from this Special Report? No problem.
Our No-Strings, Can't Lose, Must-Be-Satisfied Offer!
Alzheimer's Outlook 2014 comes with a risk-free offer of satisfaction: if you're not satisfied for any reason, simply contact Customer Service within 30 days for a prompt refund of your full purchase price of $29.95. So you risk nothing.